Anoop Misra
Anoop Misra is an expert in Endocrinology at Fortis Flt. Lt. Rajan Dhall Hospital (India). As of October 2026, ScienceLeadR ranks Anoop Misra in the top 1% of experts worldwide for Metabolic Syndrome, Hyperglycemia and Glucose Metabolism Disorders. Anoop Misra has authored 496 publications, the most recent in 2026, and is an investigator in 31 clinical trials, 14 of them ongoing. SLR score: 2,250 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Nutrition - Gastroenterology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 496
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Smoking cessation and harm reduction in type 2 diabetes: development of practical recommendations from the DiaSmokeFree Working Group. PMID 42645731 — diabetes mellitus, internal medicine, multiple chronic conditions, smoking cessation, smoking, diabetes mellitus, type 2, harm reduction | Intern Emerg Med | 2026 | 0 |
| Scientific writing in the age of artificial intelligence: trust on trial? PMID 41430538 — trust, intelligence, publishing, writing, research, artificial intelligence, confidentiality, peer review, plagiarism | Postgrad Med J | 2025 | 0 |
| South Asia's cardiometabolic burden: exposomal determinants of a health transition. PMID 42893086 — health transition | Lancet Reg Health Southeast Asia | 2026 | 0 |
| Mitophagy and Noncoding RNA Regulation in Type 2 Diabetes Mellitus: Molecular Mechanisms, Tissue-Specific Evidence and Translational Perspective. PMID 42792629 — diabetes mellitus, insulin resistance, mitochondrial dynamics, oxidative stress, biomarkers, rna, untranslated, therapeutics, mitophagy, tissues, diabetes complications, diabetes mellitus, type 2 | Biomedicines | 2026 | 0 |
| Corrigendum to "Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation" [Obesity Pillars 19 (2026) 100296]. PMID 42694998 — obesity, glucagon, therapeutics, glucagon-like peptides | Obes Pillars | 2026 | 0 |
Clinical Studies 31
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
14 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
LeadR Networks
Main global connection map